27761-19-9 Usage
Description
(Mercaptoethyl)ammonium hydrogen tartrate, also known as Cysteamine bitartrate (CAS# 27761-19-9), is a chemical compound derived from the tartaric acid family. It is characterized by its unique structure, which includes a thiol (mercapto) group and an ammonium ion. (mercaptoethyl)ammonium hydrogen tartrate exhibits properties that make it suitable for various applications in the pharmaceutical and medical industries.
Uses
Used in Pharmaceutical Industry:
(Mercaptoethyl)ammonium hydrogen tartrate is used as a therapeutic agent for the treatment of cystinosis, a rare genetic disorder characterized by the accumulation of cystine crystals in various tissues of the body. The compound acts by reducing the levels of cystine in the body, thus preventing the formation of these harmful crystals.
Additionally, (mercaptoethyl)ammonium hydrogen tartrate is used as a treatment option for other metabolic and neurodegenerative diseases. Its unique properties allow it to potentially modulate various cellular pathways and protect against the detrimental effects of these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 27761-19-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,7,6 and 1 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 27761-19:
(7*2)+(6*7)+(5*7)+(4*6)+(3*1)+(2*1)+(1*9)=129
129 % 10 = 9
So 27761-19-9 is a valid CAS Registry Number.
InChI:InChI=1/C4H6O6.C2H7NS/c5-1(3(7)8)2(6)4(9)10;3-1-2-4/h1-2,5-6H,(H,7,8)(H,9,10);4H,1-3H2/p-2
27761-19-9Relevant articles and documents
PROCESS FOR PREPARATION OF CYSTEAMINE BITARTRATE
-
Paragraph 0048; 0049; 0050, (2018/07/31)
The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
